Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) 41 the annual report for 2021 showed that the company achieved a total operating revenue of 439 million yuan, up 16.93% year-on-year. Excluding the impact of the share based payment fees to be accrued for the termination of equity incentive during the reporting period (excluding the impact of income tax), the net profit attributable to the shareholders of the listed company was 871311 million yuan, a year-on-year increase of 2.81%. It is worth noting that its R & D expenses increased significantly by 65.52% year-on-year, reaching 459019 million yuan, with full success of scientific innovation.
It is understood that Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) independently developed detection technology platforms such as routine pathology, liquid based cytology (LBP), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), PCR, etc., covering the needs of tumor screening and diagnosis from tissue, cell to protein and molecular levels. It covers the clinical needs of different diagnostic levels from cell morphology to protein expression and gene detection. As of the end of the reporting period, 570 registration / filing products related to pathological diagnosis have been developed, which can be used for the screening and diagnosis of multiple types of tumors. It is one of the enterprises with the richest technical platforms and the largest variety of products in China’s tumor screening and diagnosis industry. Moreover, some products have been certified by CE, European Union, British Standards Institute (BSI) and Japan’s Ministry of health, labor and welfare. It has established good cooperative relations with a number of authoritative hospitals, has been applied in many top three hospitals, competes with international brands, and has been widely recognized and trusted by authoritative hospitals.
In order to realize the accuracy of cervical cancer screening, promote the intellectualization of pathology department and improve the screening efficiency, Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) launched a series of digital pathology products: “real-time vision sharing system under microscope” and “love pathology” pathologist community app, and is independently developing pathology department reporting system and automatic digital slice scanning system. In addition, Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) also cooperated with Tencent to jointly develop the Artificial Intelligence Aided Diagnosis System of cervical cytology. According to the annual report, the project has completed the product R & D and finalization, and is preparing the application of product registration certificate and clinical trial.
Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) chairman Cai Xiangting revealed that in 2022, on the basis of continuing to do a good job in the core business, the company will make efforts in three strategic new businesses, including joint construction of pathology department, pathology AI system and accompanying diagnosis. Based on the core technology of the existing business, the three businesses will expand the accompanying diagnosis required by the Internet, AI technology and tumor accurate drug use, which is of great strategic significance to improve the company’s core competitiveness and seize the market opportunity.
